Literature DB >> 12890054

Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes.

Nathalie Lalevée1, Joël Nargeot, Stéphanie Barrére-Lemaire, Patrick Gautier, Sylvain Richard.   

Abstract

UNLABELLED: Effect of Dronedarone on Cardiac Na Current.
INTRODUCTION: Amiodarone (AM) is a highly effective antiarrhythmic agent used in the management of both atrial and ventricular arrhythmias. Its noniodinated analogue dronedarone (SR) may have fewer side effects than AM. In this study, we compared the effects of AM and SR on the sodium current I(Na) in human atrial myocytes. METHODS AND
RESULTS: INa was studied with the whole-cell, patch clamp technique. Both AM and SR induced a dose-dependent inhibition of I(Na) recorded at -40 mV from a holding potential of -100 mV. AM inhibited I(Na) by 41%+/- 11% (n = 4) at 3 microM, and by 80%+/- 7% (n = 5) at 30 microM. SR produced more potent block, inhibiting INa significantly at only 0.3 microM (23%+/- 10%, n = 4) and completely (97%+/- 4%, n = 4) at 3 microM. Both AM and SR had only moderate effects on voltage-dependent properties of I(Na) (current-voltage relationship, availability for activation) and had no effect on the current decay kinetics.
CONCLUSION: Both AM and SR inhibit I(Na) significantly in single human atrial cells, showing that the two drugs have Class I antiarrhythmic properties. The acute effects of SR are more potent than those of AM. The study supports the idea that the iodinated form of the molecule has no part in the acute effect of AM on Na+ channels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12890054     DOI: 10.1046/j.1540-8167.2003.03064.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  26 in total

1.  Effect of dronedarone on Na+, Ca2+ and HCN channels.

Authors:  Roman Bogdan; Heinz Goegelein; Hartmut Ruetten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01-29       Impact factor: 3.000

Review 2.  New developments in atrial antiarrhythmic drug therapy.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Nat Rev Cardiol       Date:  2010-03       Impact factor: 32.419

3.  A Cardiac Cell Outgrowth Assay for Evaluating Drug Compounds Using a Cardiac Spheroid-on-a-Chip Device.

Authors:  Jonas Christoffersson; Florian Meier; Henning Kempf; Kristin Schwanke; Michelle Coffee; Mario Beilmann; Robert Zweigerdt; Carl-Fredrik Mandenius
Journal:  Bioengineering (Basel)       Date:  2018-05-04

4.  Ventricular tachycardia and aggravation of Brugada ECG pattern in a patient with coronary artery disease and combined amiodarone and betablocker therapy.

Authors:  H Nägele; S Behrens; A Castel
Journal:  Clin Res Cardiol       Date:  2007-12-19       Impact factor: 5.460

5.  Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria.

Authors:  Alexander Burashnikov; Luiz Belardinelli; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2010-05-15       Impact factor: 6.343

Review 6.  Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

Authors:  Ahmed M A Adlan; Gregory Y H Lip
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

Review 7.  [Dronedarone: the new antiarrythmic agent?].

Authors:  J Brachmann; A-M Sinha
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2009-06

Review 8.  Novel approaches for pharmacological management of atrial fibrillation.

Authors:  Joachim R Ehrlich; Stanley Nattel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Beta1-adrenoceptor polymorphism predicts flecainide action in patients with atrial fibrillation.

Authors:  Amir M Nia; Evren Caglayan; Natig Gassanov; Tom Zimmermann; Orhan Aslan; Martin Hellmich; Firat Duru; Erland Erdmann; Stephan Rosenkranz; Fikret Er
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

Review 10.  Dronedarone for atrial fibrillation: a new therapeutic agent.

Authors:  Pawan D Patel; Rohit Bhuriya; Dipal D Patel; Bhaskar L Arora; Param P Singh; Rohit R Arora
Journal:  Vasc Health Risk Manag       Date:  2009-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.